RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
National cervical cancer screening campaign under way Today sees the kick-off of the national campaign: Let’s talk about cervical cancer – have you #done the smear test or self-test yet? This marks the first time that RIVM, Bevolkingsonderzoek Nederland and the KWF Dutch Cancer Society are launching a joint campaign to call attention to cervical cancer screening.
Self-sampling device to be sent automatically, making it easier to take part in cervical cancer screening From the first week of July, every woman turning 30 will receive a self-sampling device with their invitation for cervical cancer screening. Participants can use this device to collect their own vaginal material.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.